Association of 1,5-anhydroglucitol, a biomarker of glucose peaks, with subclinical cardiovascular disease
Embargo until
Date
2016-04-25
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Johns Hopkins University
Abstract
Background 1,5-anhydroglucitol (1,5-AG) is a biomarker of glucose peaks and has been associated with clinical cardiovascular disease. However, the association between 1,5-AG and subclinical cardiovascular disease is unknown. We investigated the association of 1,5-AG with both subclinical myocardial damage (assessed by high-sensitivity cardiac troponin T [hs-cTnT]) and atherosclerosis (assessed by carotid intima–media thickness [CIMT] and carotid plaque).
Methods We measured 1,5-AG, hs-cTnT, CIMT, and carotid plaque among 10,072 persons without diabetes and 681 persons with diabetes who attended the second examination of the Atherosclerosis Risk in Communities (ARIC) Study (baseline, 1990–1992) and characterized the associations between 1,5-AG and prevalent elevated hs-cTnT, thick CIMT, or carotid plaque using Poisson regression. Among persons with a second hs-cTnT measurement, 6 years later, (n=9,145) we used multinomial logistic regression to assess the association with incident elevation in hs-cTnT.
Findings We found that in persons with diabetes, lower 1,5-AG (<6 ug/mL) was cross-sectionally associated with elevated hs-cTnT (PR 2.06, 95%CI 1.23-3.46) and compared to higher 1,5-AG (≥10 ug/mL). Associations with the presence of carotid plaque and in persons without diabetes were less robust. Low 1,5-AG was prospectively associated with hs-cTnT (RR 2.90, 95%CI 1.23–6.85) in persons with diabetes.
Interpretation In persons with diabetes, 1,5-AG was associated with subclinical cardiovascular disease, particularly chronic subclinical myocardial damage. Our results suggest that chronic hyperglycemia together with glucose peaks may contribute to cardiac damage and atherosclerotic disease.
Description
Keywords
1,5-anhydroglucitol, high-sensitivity cardiac troponin T